A. Yu. Maksimovskaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
A. Yu. Maksimovskaya has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Andrey V. Vazhenin
South Ural State Medical University
3 shared publications - Marina M. Sarycheva
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine; South Ural State Medical University
3 shared publications A. A. Lozhkov
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
2 shared publications- D. M. Timokhina
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
2 shared publications - Ekaterina Ya. Mozerova
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine; South Ural State Medical University
2 shared publications - R. Yu. Karabut
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
2 shared publications
Latest Publications
- Open Access
- 14 December 2023
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 6 (4) , 9-17
Results of Treatment of Patients with Progression of Primary Highly Malignant Brain Gliomas During a Repeated Course of Radiation Therapy. Own Experience
Purpose: To determine the most effective option for repeated radiation therapy in patients with continued growth of primary high-grade brain glioma, taking into account the isodose distribution during the initial course of radiation therapy. Material and methods: As a result of a retrospective analysis, the results of treatment of 100 patients with confirmed progression of high-grade glioma treated at the Chelyabinsk Regional Center for Oncology and Nuclear Medicine in the period from 2010 to 2020 were evaluated. The ratio of men and women was approximately equal (56 men and 44 women). The mean age of patients of both sexes was 47.2±11.9 years. According to the histological conclusion, patients with glioblastomas (GB) prevailed (n = 58), 42 patients were diagnosed with anaplastic astrocytoma (AA). Reoperation was performed in 26 patients. Repeated radiation therapy in an independent variant was performed in 76 patients of them: 17 patients received a course of neuronal therapy in mono mode and in 17 patients in combination with external beam radiation therapy; 23 patients underwent stereotactic radiotherapy (SRS) using the CyberKnife device; in 19 cases, remote radiation therapy. In 24 cases, a chemotherapeutic component was added in addition to radiation treatment. Results: Mean time to relapse was 23 months. The median overall survival (OS) for all patients was 35 months. (DI 26.2–43.7). Indicators of 1-year OS — 85.6 %; 3-year-old — 44.1 %, 5-year-old — 26.5 %. Depending on the type of radiation therapy: the highest progression-free survival (PFS) was found with SPLT and combined photon-neutron therapy (SPNT) as in the group of patients with recurrent EH for 15, 17, and AA 24 and 40 months, respectively. Among the patients included in our study, the majority of patients (42 people) had central recurrences (in which 95 % or more of the volume of the recurrent tumor was within 100-95 % of the initial isodose), 6 had marginal relapses (20 to 80 % of the recurrent volume is within the surface of 95 % isodose), and in 2 cases a distant recurrence was recorded (less than 20 % of the recurrent volume was within 95 % of the isodose). Distant recurrences (marginal and distant) occurred within an average of 12 months, while central recurrences were diagnosed on average 26 months after the end of the course of radiation (chemoradiation) treatment. Conclusion: Thus, when analyzing our data, in all patients with continued growth of primary high-grade brain gliomas, the method of choice for a repeated course of radiation therapy is stereotactic radiation therapy or a combined course of photon-neutron therapy, which allows to overcome the existing radioresistance.
- 14 December 2023
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 6 (4) , 9-17
Open AccessResults of Treatment of Patients with Progression of Primary Highly Malignant Brain Gliomas During a Repeated Course of Radiation Therapy. Own Experience
Purpose: To determine the most effective option for repeated radiation therapy in patients with continued growth of primary high-grade brain glioma, taking into account the isodose distribution during the initial course of radiation therapy. Material and methods: As a result of a retrospective analysis, the results of treatment of 100 patients with confirmed progression of high-grade glioma treated at the Chelyabinsk Regional Center for Oncology and Nuclear Medicine in the period from 2010 to 2020 were evaluated. The ratio of men and women was approximately equal (56 men and 44 women). The mean age of patients of both sexes was 47.2±11.9 years. According to the histological conclusion, patients with glioblastomas (GB) prevailed (n = 58), 42 patients were diagnosed with anaplastic astrocytoma (AA). Reoperation was performed in 26 patients. Repeated radiation therapy in an independent variant was performed in 76 patients of them: 17 patients received a course of neuronal therapy in mono mode and in 17 patients in combination with external beam radiation therapy; 23 patients underwent stereotactic radiotherapy (SRS) using the CyberKnife device; in 19 cases, remote radiation therapy. In 24 cases, a chemotherapeutic component was added in addition to radiation treatment. Results: Mean time to relapse was 23 months. The median overall survival (OS) for all patients was 35 months. (DI 26.2–43.7). Indicators of 1-year OS — 85.6 %; 3-year-old — 44.1 %, 5-year-old — 26.5 %. Depending on the type of radiation therapy: the highest progression-free survival (PFS) was found with SPLT and combined photon-neutron therapy (SPNT) as in the group of patients with recurrent EH for 15, 17, and AA 24 and 40 months, respectively. Among the patients included in our study, the majority of patients (42 people) had central recurrences (in which 95 % or more of the volume of the recurrent tumor was within 100-95 % of the initial isodose), 6 had marginal relapses (20 to 80 % of the recurrent volume is within the surface of 95 % isodose), and in 2 cases a distant recurrence was recorded (less than 20 % of the recurrent volume was within 95 % of the isodose). Distant recurrences (marginal and distant) occurred within an average of 12 months, while central recurrences were diagnosed on average 26 months after the end of the course of radiation (chemoradiation) treatment. Conclusion: Thus, when analyzing our data, in all patients with continued growth of primary high-grade brain gliomas, the method of choice for a repeated course of radiation therapy is stereotactic radiation therapy or a combined course of photon-neutron therapy, which allows to overcome the existing radioresistance.
- Open Access
- 30 August 2021
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 20 (4) , 91-98
RADIATION-INDUCED TOXICITY IN BREAST CANCER PATIENTS TREATED WITH TRASTUZUMAB-BASED CHEMOTHERAPY
The aim of the study was to determine and analyze the most significant risk factors for developing cardiac, pulmonary and skin toxicities among patients who received concurrent radiation therapy and chemotherapy with trastuzumab.Material and methods. The study included 66 patients with histologically verified invasive intermediate or low-grade breast carcinoma, who received radiation therapy and chemotherapy with trastuzumab from 2018 to 2019. The average age of the patients was 53.1 ± 4.2 years. Locally advanced stage iii a and iii b breast cancer was the most common (52 %) followed by stage ii a and ii b cancer (36 %). The lvef of all patients was ≥50 %. All patients received neoadjuvant chemotherapy with anthracyclines and/or taxanes. Radiation-induced side effects were assessed using the rtog/eortc scoring criteria. Dose-volume histogram (dvh) of radiotherapy planning was matched to the quantec criteria.Results. Radiation-induced pulmonitis was observed in 2 patients within 2 to 6 months after the completion of radiation therapy. A 10 % reduction in lvef was observed in 3 patients, while a 20 % decrease in ef was not found. Long qt syndrome was observed in 3 patients, and it was accompanied by clinical manifestations in 2 patients. When evaluating the echo-cg protocols after treatment, normal lv diastolic function was recorded in 39 patients, moderate diastolic dysfunction (lv dd) in 27, and 1 patient had severe lv dd. When assessing the dose received by the lv myocardium, the excess of the average dose to the myocardium was present both on the left and on the right. Only in 16 % of cases, left myocardial irradiation met criterion v 25. Clinically, arrhythmias, unstable angina pectoris, and other manifestations of coronary artery disease were mostly observed among patients with left-sided breast cancer. Significant factors for the development of cardiotoxicity were left-sided breast cancer, previous chemotherapy with anthracyclines and/or taxanes, as well as myocardial doses. The occurrence of radiation pulmonitis did not show an obvious relationship with any factor, while the body mass index (bmi) of >30 was a significant factor for the occurrence of radiation-induced skin damage.Conclusion. The combination of radiation therapy and trastuzumab was associated with an acceptable risk of cardiotoxicity. Monitoring of the cardiovascular system parameters during treatment and detection of early signs of cardiotoxicity were shown to be of great importance.
- 30 August 2021
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 20 (4) , 91-98
Open AccessRADIATION-INDUCED TOXICITY IN BREAST CANCER PATIENTS TREATED WITH TRASTUZUMAB-BASED CHEMOTHERAPY
The aim of the study was to determine and analyze the most significant risk factors for developing cardiac, pulmonary and skin toxicities among patients who received concurrent radiation therapy and chemotherapy with trastuzumab.Material and methods. The study included 66 patients with histologically verified invasive intermediate or low-grade breast carcinoma, who received radiation therapy and chemotherapy with trastuzumab from 2018 to 2019. The average age of the patients was 53.1 ± 4.2 years. Locally advanced stage iii a and iii b breast cancer was the most common (52 %) followed by stage ii a and ii b cancer (36 %). The lvef of all patients was ≥50 %. All patients received neoadjuvant chemotherapy with anthracyclines and/or taxanes. Radiation-induced side effects were assessed using the rtog/eortc scoring criteria. Dose-volume histogram (dvh) of radiotherapy planning was matched to the quantec criteria.Results. Radiation-induced pulmonitis was observed in 2 patients within 2 to 6 months after the completion of radiation therapy. A 10 % reduction in lvef was observed in 3 patients, while a 20 % decrease in ef was not found. Long qt syndrome was observed in 3 patients, and it was accompanied by clinical manifestations in 2 patients. When evaluating the echo-cg protocols after treatment, normal lv diastolic function was recorded in 39 patients, moderate diastolic dysfunction (lv dd) in 27, and 1 patient had severe lv dd. When assessing the dose received by the lv myocardium, the excess of the average dose to the myocardium was present both on the left and on the right. Only in 16 % of cases, left myocardial irradiation met criterion v 25. Clinically, arrhythmias, unstable angina pectoris, and other manifestations of coronary artery disease were mostly observed among patients with left-sided breast cancer. Significant factors for the development of cardiotoxicity were left-sided breast cancer, previous chemotherapy with anthracyclines and/or taxanes, as well as myocardial doses. The occurrence of radiation pulmonitis did not show an obvious relationship with any factor, while the body mass index (bmi) of >30 was a significant factor for the occurrence of radiation-induced skin damage.Conclusion. The combination of radiation therapy and trastuzumab was associated with an acceptable risk of cardiotoxicity. Monitoring of the cardiovascular system parameters during treatment and detection of early signs of cardiotoxicity were shown to be of great importance.
- Open Access
- 2 May 2021
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 20 (2) , 77-84
NEUTRON RADIATION THERAPY IN THE TREATMENT OF RECURRENT HIGH-GRADE GLIOMA
НЕЙТРОННАЯ ЛУЧЕВАЯ ТЕРАПИЯ В ЛЕЧЕНИИ РЕЦИДИВОВ ВЫСОКОЗЛОКАЧЕСТВЕННЫХ ГЛИОМ ГОЛОВНОГО МОЗГА
- 2 May 2021
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 20 (2) , 77-84
Open AccessNEUTRON RADIATION THERAPY IN THE TREATMENT OF RECURRENT HIGH-GRADE GLIOMA
НЕЙТРОННАЯ ЛУЧЕВАЯ ТЕРАПИЯ В ЛЕЧЕНИИ РЕЦИДИВОВ ВЫСОКОЗЛОКАЧЕСТВЕННЫХ ГЛИОМ ГОЛОВНОГО МОЗГА